Jingzhang Li

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 121 citations

Medicine, Molecular Genetics, Oncology +17

MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells

Gangling Tong, Boran Cheng, Jingzhang Li et al. · Cancer Medicine · 2019 · 42 citations · Full text

Medicine, Cancer Biology, Oncology +17

Generation of dual functional nanobody-nanoluciferase fusion and its potential in bioluminescence enzyme immunoassay for trace glypican-3 in serum

Sheng Yü, Zhenfeng Li, Jingzhang Li et al. · Sensors and Actuators B Chemical · 2021 · 39 citations · Full text

Life Sciences, Biotechnology, Molecular Biology +12

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Caicun Zhou, Ziping Wang, Meili Sun et al. · Nature Cancer · 2023 · 32 citations

Medicine, Oncology, Pharmacotherapy +12

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

Yuankai Shi, Shiman Wu, Ke Wang et al. · Journal of Thoracic Oncology · 2022 · 30 citations · Full text

Medicine, Oncology, Pharmacology +13